Echo IQ: A Fully Funded, FDA-Cleared Cardiac-AI Company Scaling EchoSolv into the US
- Noel Ong
- 5 days ago
- 12 min read
Three announcements in eight days — an exclusive data licence with Advara, a ~A$110 million placement, and a strategic investment from Pro Medicus — have left the cardiac-AI company funded, validated, and armed with a hard-to-replicate data asset as it pushes into the United States.
Echo IQ Limited (ASX: EIQ) has packed three material announcements into eight days. On 2 July 2026, it executed a binding exclusive data licensing agreement with Advara HeartCare, Australia's largest private cardiovascular provider, securing access to up to one million de-identified echocardiography studies to train its next generation of AI.
That followed firm commitments on 1 July for a ~A$110 million placement at A$1.45 per share, and a binding Heads of Agreement on 25 June with global imaging leader Pro Medicus (ASX: PME) for a strategic investment of up to A$20 million and a proposed US reseller partnership.
The run of news has landed against one of the ASX's standout share-price performances of 2026: EchoIQ climbed from around A$0.35 in mid-January to an all-time high of A$1.875 on 25 June — roughly a fivefold gain in half a year — for a market capitalisation near A$1 billion.
Figure 1: Echo IQ Share Price Chart (Source: Google Finance)
At a Glance
Item | Details |
|---|---|
Company | Echo IQ Limited (ASX: EIQ) — Sydney-based AI and medical-technology company in cardiac diagnostics. Formerly Houston We Have Limited; renamed December 2021. |
Flagship | EchoSolv — an AI clinical decision-support suite that reads the measurements from a standard echocardiogram (without image analysis) to help clinicians detect structural heart disease, led by EchoSolv AS (aortic stenosis) and EchoSolv HF (heart failure). |
The news | Three announcements in eight days: an exclusive Advara data licence (2 July) for up to 1m echo studies; a ~A$110m placement (1 July) at A$1.45/share; and a binding HOA with Pro Medicus (25 June) for up to A$20m plus a proposed US reseller deal. |
Why it matters | The raise and the Pro Medicus investment fund the US commercialisation push and add a blue-chip validator and distribution channel; the Advara licence builds a proprietary data moat for the next generation of EchoSolv products. |
The raise | ~A$110m at A$1.45 (an 8.8% discount to the last traded price on 26 June); 75,862,069 new shares, ~11.5% of current issued capital. Ord Minnett sole lead manager, Morgans co-manager. Settlement 6 July; trading 7 July. |
Pro Medicus investment | Initial A$10m via secured convertible notes; option for a further A$10m on FDA clearance of EchoSolv HF. 12.5% p.a. (compounding daily), 24-month maturity, conversion capped at A$1.05; 0.75 options per note at A$1.35. |
Data assets | Advara HeartCare exclusive licence — 500,000 to 1,000,000 de-identified echocardiography studies (initial 3-year term, HREC-conditional), complementing the existing NEDA longitudinal outcomes database. |
Regulatory status | EchoSolv AS: FDA 510(k) cleared. EchoSolv HF: FDA submission lodged, outcome expected in the near term. |
Key partners | Pro Medicus (proposed US reseller), Mayo Clinic (validation study and distribution pathway), Advara HeartCare (data), plus deployments including Mount Sinai. |
Leadership | Dustin Haines (CEO, US-based, ex-Gilead Sciences); Andrew Grover (Executive Chair). |
Market performance | Standout 2026 performer: ~A$0.35 (mid-January) to an all-time high of A$1.875 (25 June); ~A$1bn market cap; placement struck at A$1.45. (Indicative; moves with the share price.) |
Next steps | Definitive Pro Medicus documentation (coming weeks); placement settlement 6–7 July; HREC approval and data delivery under the Advara licence; FDA outcome on EchoSolv HF. |
The 60-Second Pitch - Echo IQ
Echo IQ is an Australian medical-technology company applying artificial intelligence to cardiology, under the banner “know each heart by its numbers.” Its EchoSolv platform works from the measurements already captured in a standard echocardiogram - delivering measurement-based decision support without image analysis - and returns a risk assessment in seconds, aiming to lift the accuracy and consistency of diagnosis for conditions that are common, serious and chronically underdiagnosed.
Because the software reads structured measurements rather than raw imaging, it is built to slot into existing workflows with minimal disruption, and its models were developed on one of the world's largest echocardiographic datasets, exceeding 200 million measurements.
The lead product, EchoSolv AS, targets severe aortic stenosis, a valve disease with a high untreated mortality rate where roughly half of sufferers are unaware they have it and holds FDA 510(k) clearance for the US market. A second product, EchoSolv HF, addresses heart failure, a far larger clinical and commercial opportunity, and is under active FDA review.
The investment case rests on four legs: a validated technology with published performance data, a regulatory pathway already open for one product and advancing for a second, a US commercial engine now being assembled through partnerships and capital, and — following the Advara deal — a proprietary data foundation to feed future products. The company is led by CEO Dustin Haines, a US-based executive who joined from Gilead Sciences, alongside Executive Chair Andrew Grover.
The Placement: Terms and Use of Funds
The placement will issue 75,862,069 new fully paid ordinary shares at A$1.45 each, representing approximately 11.5% of Echo IQ's current issued capital and raising close to A$110 million. The price sits at an 8.8% discount to the company's last traded price on 26 June - implying a last close of roughly A$1.59 - a comparatively tight discount for a raise of this size and a reflection of the strength of the bid. Settlement is scheduled for Monday 6 July, with the new shares expected to begin trading on Tuesday 7 July, ranking equally with existing shares. Ord Minnett acted as sole lead manager and Morgans as co-manager.
The company has framed the use of funds around commercial acceleration rather than survival. Net proceeds are earmarked to:
strengthen the balance sheet;
accelerate US commercial execution and expand deployment of EchoSolv across US health systems;
continue product development and pursue complementary strategic opportunities; and
fast-track development of a broader cardiovascular AI platform beyond the current suite.
On an enlarged base of roughly 737 million shares, the placement price implies an indicative market capitalisation above A$1 billion — a figure that has moved sharply in recent weeks, with the stock reaching an all-time high on the day the Pro Medicus agreement was announced. The dilution to existing holders is real at around 11.5%, but the discount is modest, and the capital is directed at the commercial build-out the story requires.
The Pro Medicus Partnership
The 25 June agreement is the most strategically loaded of the three announcements. Pro Medicus is widely regarded as one of Australia's most successful healthcare technology companies and a global leader in enterprise imaging through its Visage platform, with mission-critical deployments across major US health systems and academic medical centres.
Its decision to both invest in Echo IQ and act as a reseller is the kind of third-party endorsement that is difficult to manufacture, and it gives EchoSolv a potential route into an established enterprise customer network.
The investment is structured as secured convertible notes, with the second tranche aligned to FDA clearance of EchoSolv HF — the company's single largest near-term catalyst. The key terms are summarised below.
In April, Echo IQ had confirmed the deployment of EchoSolv AS into Mount Sinai Health System, a major healthcare network based in New York, United States.
Table 1: Pro Medicus convertible notes — Key terms
Item | Details |
Instrument | Secured unlisted convertible notes, secured over all group assets, with specific security over the aortic stenosis and heart failure algorithms. |
Initial subscription | 10,000,000 notes at A$1 face value (A$10m). |
Second tranche | Option for a further 10,000,000 notes (A$10m), exercisable within 12 months of FDA clearance of EchoSolv HF; Pro Medicus is not obliged to proceed. |
Interest | 12.5% per annum, compounding daily, payable at maturity. |
Maturity | 24 months from issue; no voluntary prepayment permitted. |
Conversion | Lower of a A$1.05 valuation cap or the 5-day VWAP at the time of conversion, subject to a floor (minimum 1,000,000 notes per conversion). |
Options | 0.75 unlisted options per note, exercise price A$1.35, expiring 24 months from note issue. |
Approval | Issued under ASX Listing Rule 7.1 placement capacity; no shareholder approval required. |
Two features warrant attention. First, the arrangement is a binding Heads of Agreement, not definitive documentation — the parties are still finalising legal terms, and Pro Medicus is not obliged to fund the second A$10 million even if FDA clearance is obtained. Second, the A$1.05 conversion cap sits well below both the A$1.45 placement price and the levels at which the stock has recently traded, meaning any conversion would occur at a discount to market and could dilute existing holders more than the headline numbers suggest. Neither point undoes the strategic value of the partnership, but both belong in a clear-eyed reading of the terms.
The Advara Data Licence and the AI Moat
On 2 July, Echo IQ executed a definitive exclusive data licensing agreement with Advara HeartCare, Australia's largest private cardiovascular diagnostics provider. Advara runs a national network of cardiology clinics supporting more than 750,000 patient interactions a year, and the agreement gives Echo IQ exclusive access to between 500,000 and 1,000,000 de-identified echocardiography studies - imaging together with linked clinical information such as referral pathways, diagnostic findings and outcomes — sourced from that network. The initial term is three years, with an option to extend for a further three, and the agreement includes IP protections under which Echo IQ retains ownership of all AI outputs.
The strategic logic is about defensibility rather than immediate revenue. Echo IQ frames the Advara licence as complementary to its existing National Echo Database Australia (NEDA) relationship: NEDA provides one of the world's largest longitudinal cardiovascular outcomes datasets, central to clinical validation and regulatory evidence, while Advara supplies the large-scale real-world imaging data best suited to training and refining AI models. Together, the company argues, the two assets span the full pipeline from product discovery and algorithm development through validation to deployment - a proprietary, difficult-to-replicate data foundation as cardiovascular AI moves from single-disease tools toward multi-condition platforms. The exclusivity is doing real work here: it is as much about denying competitors the data as about feeding Echo IQ's own pipeline.
The important qualifier is that this is a foundation for future products, not current ones. Initial delivery is conditional on Advara securing Human Research Ethics Committee (HREC) approval and the parties agreeing data-quality specifications; Advara has warranted a floor of 500,000 studies with at least 70% meeting those specifications, and if approval or specifications are not settled within 60 days of commencement, Echo IQ may terminate and recover its licence fees. The value of the asset therefore depends on both the data arriving as expected and Echo IQ converting it into cleared, commercialised algorithms over time.
The Commercial and Regulatory Engine
Behind the capital and the data sits the operating story. EchoSolv AS has held FDA 510(k) clearance since late 2024, supported by validation work including a Harvard Beth Israel study of more than 31,000 patients (Figure 2)
EchoSolv HF is the larger prize: heart failure is one of the most expensive conditions in US healthcare, only around half of cases are accurately diagnosed, and Echo IQ's heart-failure model was independently validated through the Mayo Clinic Platform's Validate program, reporting sensitivity of 99.5% and specificity of 91.0% across roughly 17,000 patient echocardiograms. That study cleared the final clinical hurdle before the FDA submission, whose outcome the company expects in the near term.
The Mayo Clinic relationship has since broadened into a distribution pathway, with an expanded agreement enabling Mayo to resell and distribute EchoSolv HF following clearance, alongside a separate cardio-oncology research collaboration. Layered on top are integrations reaching US cardiology networks and deployments into health systems including Mount Sinai.
The Pro Medicus reseller arrangement, if it completes, would add a further enterprise channel. The through-line is consistent: Echo IQ is assembling recognised US distribution partners ahead of the EchoSolv HF decision, so that a clearance can be converted into deployment rather than merely announced.
Figure 2: EchoSolv AS and Cardiologists (Source: EIQ Website)
Management Commentary
CEO Dustin Haines framed the placement as a step-change in the company's commercial phase.
“This Placement represents the next step in Echo IQ's commercial evolution and reflects the strong strategic progress the Company has delivered over recent years,” he said,
Pointing to FDA clearance of EchoSolv AS, expansion across US health systems, and partnerships with organisations including Mayo Clinic and Pro Medicus. He added that, following completion of the placement, the company expects to accelerate deployment of EchoSolv across the US, expand its commercial organisation and increase implementation capacity at a time when customer engagement continues to build.
On the Pro Medicus agreement, Haines described a milestone that extends well beyond the money.
“The execution of this binding Heads of Agreement with Pro Medicus represents a transformational milestone for Echo IQ and a significant validation of both our technology and long-term commercial strategy,” he said.
He characterised the arrangement as an opportunity to leverage an established healthcare platform, trusted customer relationships and an experienced commercial organisation with deep US penetration, aligning Pro Medicus's participation with FDA clearance of EchoSolv HF as one of the company's most significant potential value catalysts.
On the Advara licence, Haines positioned the dataset as a long-term capability rather than a near-term product, noting that while NEDA remains a world-class platform for clinical validation and outcomes research, the Advara imaging data brings “something different and highly complementary” that can be used to train and develop future generations of cardiovascular AI. Advara CEO Dr David O'Donnell framed the collaboration within his organisation's research mission, noting that appropriately governed and de-identified real-world data can support the responsible development of technologies designed to improve patient care.
Samso Concluding Comments
These three announcements is showing that this is a company executing on every front at once. In eight days, Echo IQ has secured the capital to fund its US push, the endorsement of a blue-chip healthcare-imaging partner, and exclusive access to one of Australia's largest cardiovascular imaging datasets.
Funded, validated and building a proprietary data moat, it has removed the balance-sheet question from the EchoSolv HF catalyst and strengthened its long-term competitive position - and the market has rewarded the progress, with the shares among the ASX's best performers this year.
Readers need to resist treating the news intent as banked value. The Pro Medicus arrangement is a Heads of Agreement, not definitive documentation, and its convertible-note terms - a A$1.05 conversion cap below market, a 12.5% compounding coupon, options at A$1.35 - carry a real dilution cost.
The Advara dataset is conditional on ethics approval and yet to be delivered, and data access is a foundation for future products, not proof of them. After a fivefold re-rating, much of this optimism is already in the price.
The strategy is sound, and the assets are real, but the value now turns on execution the company does not yet fully control: the FDA's decision on EchoSolv HF, the delivery and conversion of the Advara data, and the translation of validated technology into recurring US revenue. The pieces are in place; the proof is still ahead.
The share price is definitely indicating a path to success and I cannot ignore the fact that since Samso started covering the EIQ story, the share price has almost done a 10 bag. Will this mean that it will continue or be a sign of some profit taking, that is a question that needs to be asked. I strongly suggest DYOR.
The Samso Way – Seek the Research
Here at Samso, we pride ourselves on delivering content for investors that is independent and informed by over three decades of experience in the industry. Our content is well-researched and is only created if I see merit in discussing the company's story.
Our mission is simple: cut through the noise and spotlight what matters—genuine stories, grounded insights, and real opportunity.
Our content is well-researched and is only created if the team sees merit in discussing the company or concept. Investors can explore our three core platforms:
There may be numerous paths to success in investing, but the common thread among successful individuals is that they remain committed to making informed decisions. Equip yourself with the right knowledge and tools, and you will be well on your way to achieving your financial goals.
Most importantly, investors need to be absolutely diligent in understanding their own risk-reward tolerance and capabilities. Never bite off more than you can chew. As they say, Rome wasn’t built in a day, and the Great Wall stood because it took centuries to complete.
The Samso Philosophy:
Stay curious. Stay sharp. And remember—digging deeper always uncovers the real value.
In Life, there is no such thing as a Free Lunch.
Never bite off more than you can chew is my parting comment.
Happy Investing, and the only four-letter word you need to know is DYOR.
To support our independent nature of our work, please head over to our Support Page and give us a helping hand in any of the ways listed. This is a new initiative for the Samso Platform, and it was always the concept of Samso when we started this journey in 2018.
Disclaimer
The information or opinions provided herein do not constitute investment advice, an offer, or solicitation to subscribe for, purchase, or sell the investment product(s) mentioned herein. It does not take into consideration, nor have any regard to your specific investment objectives, financial situation, risk profile, tax position and particular, or unique needs and constraints.
Share to Grow: Your Bonus
Samso has just released an eBook: How to Add Value to your Share Portfolio
|A lesson on geological models sought by mining companies that gives insight and an understanding of which portfolios are better - and potentially more lucrative – investments. Click here to download this eBook.|
If you find this article informative and useful, please help me share the information. I try to write about topics that are interesting and have the potential to be of investment value. It is not easy to find stories that fit those parameters. If you or your organisation sees the benefit of what Samso is trying to achieve and has a need to share your journey, please contact me at noel.ong@samso.com.au.
Samso is a trusted platform that equips dedicated investors with up-to-date industry knowledge and insigh0ts from top CEOs and thought leaders. By staying informed on business advancements and market trends, investors can enhance their financial decisions through a combination of expert guidance and their own research.
Samso News | www.samso.com.au | An Investor Lens on ASX-Listed Companies
Comments